News
Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...
Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...
Yet exercise can sometimes be deceptive. Years before starting Virta Health, while cofounding the real-estate company Trulia, ...
PRINCETON, NJ, USA I July 15, 2025 I Palatin Technologies, Inc. (OTCQB: PTNT), a biopharmaceutical company developing first-in-class medicines based on ...
The game-changing weight loss jabs have ushered in a new era in the war on obesity, but have also been linked to other health ...
Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...
2d
The Brighterside of News on MSNWeight-loss drug Tirzepatide significantly slows breast cancer growth, study findsKey Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer.
For adults with obesity treated with once-weekly tirzepatide, cardiometabolic risk factor improvements were positively ...
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.
Popular weight loss medications like Ozempic can help reverse low testosterone levels in men with obesity or Type 2 diabetes, ...
2d
Vietnam Investment Review on MSNAscletis Completes Dosing in US Obesity Drug Combo TrialAscletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results